VPS50 subunit of EARP/GARPII complexGenealiases: CCDC132 · NEDMSC · VPS54L
Q-omics provides the consensus-scored VPS50 profile across patient tissues and cancer cell-line models. VPS50 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, VPS50 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, VPS50 RNA expression shows 20,521 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where VPS50 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VPS50 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VPS50 survival associations across molecular data types. VPS50 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VPS50 RNA expression–survival associations across cancer types. High VPS50 expression shows unfavorable associations in LIHC, MESO and UVM, but favorable associations in KIRC, BRCA and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for VPS50 RNA expression.
This table summarizes VPS50 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for VPS50. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VPS50 shows lower tumor expression in THCA and KIRC and higher tumor expression in LIHC, HNSC, CHOL and BLCA. The THCA box plot shows higher VPS50 RNA expression in normal versus tumor tissue (log2 FC = −0.600, t-test p < 0.001).
This table shows molecular features associated with VPS50 in patient tissues and cancer cell lines. In patient samples, VPS50 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, VPS50 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
